Sensyne Health announces Tony Bourne to its Board as upcoming Independent Director

– UK, Oxford – Sensyne Health plc (LON: SENS), the Clinical AI company, today announced the appointment of Tony Bourne to the Board as Independent Non-Executive Director effective from 31 January 2021.

“I’m delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth – building an innovative world class clinical data and artificial intelligence company.” said Board Chairman, Sir Bruce Keogh.

Tony Bourne will also serve as Chair of the Remuneration Committee.

About Tony Bourne

Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Before this, he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.

Tony currently serves as Chair of CW+ and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.